FDA Clearance Tracker · P160019-S014
Elecsys HBsAg II, PreciControl HBsAg II, Elecsys HBsAg Confirmatory Test, Elecsys HBsAg II Auto Confirm, PreciControl HB
Last checked: Nov 20, 2026Latest source record: Apr 24, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Apr 24, 2023
Approved
Time to decision
165 days
Received Nov 10, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class II
The decision
- FDA number
- P160019-S014
- Device name
- Elecsys HBsAg II, PreciControl HBsAg II, Elecsys HBsAg Confirmatory Test, Elecsys HBsAg II Auto Confirm, PreciControl HB
- Applicant
- Roche Diagnostics, Inc.
- Applicant location
- Indianapolis, IN
- Received
- Nov 10, 2022
- Decided
- Apr 24, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160019
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the migration of Elecsys HBsAg II from the cobas e 601 to the cobas e 402 analyzer.
Source documents
Other decisions for Roche Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P160019 · Decided Dec 23, 2016 · 175 days after receipt
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.